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Abstract
Background: Breast cancer treatment success depends upon prolonging survival with effective treatment, and constant moni-
toring of recurrence. Survival rate can well be improved by better understanding of prognostic factors, preventive measures, and
effective treatments together with follow-up and post-treatment care.
Objectives: This study is aimed to know prognostic factors effective in recurrence and death in Iranian breast cancer patients.
Methods: This is a retrospective study conducted by reviewing data acquired from 1604 female breast cancer patients who were ad-
mitted to Cancer Research Center at Shahid Beheshti University of Medical Sciences between October, 1982 and March, 2014. During
the follow-up, after diagnosis, 313 patients experienced recurrence then were classified into two groups: early recurrence, less than
1 year and late recurrence after 5 years. We analyzed prognostic factors of recurrence in each groups and evaluated effective factors
of death in this patients.
Results: Median age of patients at diagnosis was 50 years. Median follow up time was 4.33 years (range: 0.005-24.9 years). Of these
patients, 210 (67.09 %) and 76 (24.28%), developed distant and loco -regional recurrence. Among 313 patients, 62 (21/60%) and 69
(24/04%) had early and late recurrence. In the univariate analysis, tumor grade, stage of disease, ER and PR status, axillary lymph
node involvement and lymph vascular invasion were the prognostic factors affecting recurrence in patients, but in the multivariate
analysis, ER/PR status was the most important independent prognostic factor affecting the early recurrence and stage of disease were
prognostic factors in late recurrence. In all of the recurrent patients, 56.86% (178 individuals) survived and 43.13% (135 individuals)
died at the end of follow-up period. The most important factors of death were histologic grade, disease free survival time, site of
recurrence and age of disease.
Conclusions: Biologic marker, estrogen and progesterone receptors status, had most influence in early recurrence, unlike late re-
currence, stage of disease had a more important role. However, lymph vascular invasion has been an effective factor either in early
or late recurrence. As a result of studying effective factors in death of these patients, recurrence site, DFS, pathologic grade and
patients’ age at the time of recurrence came to be effective. Knowing more about affecting factors on recurrence and the death of
patients with recurrence, one can try to enhance survival and quality of life in patients by adopting more effective treatments.
Keywords: Breast Cancer, Recurrence, Metastasis, Risk Factor, Prognosis
1. Background
Breast cancer is one of the most prevalent types of
cancer across the globe with 1.67 million newly diagnosed
cases. It comprises 25% of all cancer cases and is the most
prevalent among Iranian women (1). When it comes to inci-
dence, and death rate, populations around the globe vary
widely based on age, sex, race, ethnicity, economic-social
status, geographic location, and marital status (2, 3).
In Iran, according to the cancer registry system, breast
cancer with 24.8% distribution is among the most preva-
lent cancer types in women. The maximum distribution in
Iran is in 4 and 5th life decades, which is at least a decade
lower than the global rate (4). As reported by Globocan
2012, there are 9,795 new cases annually (1).
A chief factor in decreasing survival rate in breast can-
cer patients is recurrence (5). Recurrence risk is measured
by a collection of breast cancer natural history, prognos-
tic, anatomic, biological factors, and the type of treatment
(6). Seven retrospective studies were conducted on 3585
breast cancer patients to investigate recurrence risk. Ac-
cording to the results, the maximum risk is in the first two
years with a steep reduction to 5 years and then it gradually
moves on to 12 years (7). Generally, a-third of recurrence
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International License (http://creativecommons.org/licenses/by-nc/4.0/) which permits copy and redistribute the material just in noncommercial usages, provided the
original work is properly cited.
U
co
rr
c
 Pr
oo
f
Esmaeil Akbari M et al.
cases are loco regional and the rest are distant metastasis
(8).
The average rate of survival in patients with breast can-
cer metastasis is 18 - 24 months and 10% - 15% of patients ex-
perience early recurrence which is recurrence within two
primary years after the treatment. Also, 50% of patients
suffer from late recurrence after 5 years (9). Thanks to
advancements in early detection and breast cancer treat-
ments, long time survival is expected and in turn it will be
of great interest for researchers (10).
Breast cancer is clinically a heterogeneous disease and
is affected by a variety of factors (11). Primary tumor
size, lymph node involvement, estrogen, progesterone and
HER2 receptors are prognostic markers that play roles in
recurrence and metastasis. Yet it seems that their con-
cordance, recurrence likelihood, and metastasis rate vary
under the effect of other factors. One can hypothesize
that metastasis, especially in more invasive cancer types,
is more likely to be an innate feature of the tumor regard-
less of its direct activity based on its size or local invasion
(12, 13). Here, we studied the factors effective on early re-
currence less than 1 year of treatment and compared them
with prognostic factors effective on late recurrence after 5
years. Moreover, the factors contributing to the patients’
death were studied.
2. Objectives
This study aims to investigate the affecting factors on
too early recurrence and late recurrence to identify a sub-
category of patients with exposure to higher risk of re-
currence, so that more invasive treatments could be pre-
vented and replaced by more appropriate ones. In this way,
unnecessary diagnostic tests in care and follow up will be
ruled out. Finally, having known effective factors in de-
creasing survival in patients with recurrence, we must en-
hance survival and quality of life in patients by adopting
effective treatments.
3. Methods
This retrospective study was conducted reviewing data
acquired from 1604 female patients suffering from breast
cancer diagnosed in cancer research center at Shahid Be-
heshti University of Medical Sciences. Exclusion criteria
were being male, stage 4 of the disease at the time of di-
agnosis, and pathology of DCIS.
This retrospective study was conducted by investigat-
ing medical files of patients by a trained nurse. The data
were collected in an excel worksheet. Factors investigated
in this study include age, estrogen and progesterone re-
ceptor, human epidermal growth factor receptor 2 status,
lymph node status, stage of disease, tumor grade, lymph
vascular invasion with pathological data registered in pa-
tients’ file, survival without disease after primary treat-
ment acquired from the files, recurrence site spotted in ex-
aminations, imaging, and biopsy. Statistical data revealed
the relation between these factors and breast cancer pa-
tients’ survival.
Receptors’ status was determined via patients’ patho-
logical report following primary tumor biopsy. Her2 was
determined by means of IHC test. In case the test results
were 0 or +1, they were recognized negative. But in case
they were +3, they were considered her2 positive. +2 case
were re-examined by FISH or CISH tests. Disease free sur-
vival (DFS) was defined as the time interval between diag-
nosis, and recurrence. It was categorized in three groups
of 1 year, 1 to 5 years, and more than 5 years.
The patients were treated by surgery (modified radical
mastectomy or breast conserving surgery), adjuvant ther-
apy and hormone therapy according to stage of disease
and receptor status. Once the treatment course was over,
the patients were examined and para-clinically evaluated,
every six months for two years and yearly afterwards. In
case of clinical suspicion or detection of any symptoms, pa-
tients would have undergone tests to identify recurrence,
for example, if the patient had some pain in bones or high
alkaline phosphatase, bone scan was done. Or in case of
suspicion with the liver or abdomen problems, CT scan
from abdomen, pelvis or thorax was taken and sometimes
biopsy was to identify recurrence. Of these patients, 313 ex-
perienced recurrence in the follow up period whose data
were collected and analyzed. Recurrence sites were catego-
rized as: 1. Loco regional recurrence including recurrence
in breast skin and soft tissues, chest, or in neck lymph
nodes, and Axillae; 2. Bone recurrence; 3. Visceral recur-
rence (involvement of liver, lung, brain and other distant
organs). The mentioned variables were analyzed as uni-
variate and multivariate.
This study was aimed to find the factors effective in
recurrence in breast cancer patients compared with pa-
tients without recurrence, to detect patients with early re-
currence (DFS < 1 year) and patients with late recurrence
(DFS > 5 years), to compare prognostic factors effective in
too early recurrence and late recurrence in these patients,
and finally to study factors effective in the patients’ death.
3.1. Data Analysis
The data acquired from the patients was analyzed by
STATA version 12. The effects of variables on overall recur-
rence and then their effects on early and late recurrence
was evaluated by univariate and multivariate cox regres-
sion model analysis. The data were significant with P <
2 Iran J Cancer Prev. In Press(In Press):e5747.
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0.05. Kaplan-Meier curve was used to present the relations
between variables with survival without disease (DFS).
4. Results
At the end of the follow-up period, an analysis showed
that of 1604 patients with breast cancer, 313 experienced
recurrences (Table 1). The median age of patients was
50 years (range: 24.96 - 84.31 years). After breast cancer
diagnosis, surgical treatment was done on the patients.
56.79% patients underwent breast conserving surgery and
43.21% underwent modified radical mastectomy. Neo ad-
juvant chemotherapy was administered to 17.44% patients
and 78.10% patients received adjuvant chemotherapy. Ra-
diotherapy was administered to 94.48% patients and hor-
monal therapy was done in 71.69% total patients and 97.54%
receptor positive patients. Among 313 patients with recur-
rence, 210 patients (67.09%) and 76 (24.28%) were involved
with distant and loco regional recurrence. The median
follow-up time was 4.33 years (range: 0.005-24.9 years). Ta-
ble 2 shows distribution of recurrence site. The most preva-
lent distant metastasis was seen in bone metastasis (40.95%
of distant metastasis and 27.4%of recurrence patients). Me-
dian interval for recurrence development or DFS was 3.6
years (range: 0 - 24.18 years, standard deviation = 3.77). Dis-
ease free survival (DFS) was 96% in one year after treatment
and 80% in 5 years. 54% of relapse eventuated between 1 - 5
years after treatment (Table 3).
Univariate analysis showed that prognostic factors ef-
fective on recurrence including age below 40, higher
stages of disease, higher grades, lymph vascular invasion,
larger tumor size, negative estrogen and progesterone re-
ceptors’ status, and nodal ratio > 0.25 had significant cor-
relations with recurrence (Table 4).
Stage 3 to 2 (P = 0.000, HR = 5.002)), stage 2 to 1 (P =
0.044, HR = 1.93), grade 3 to 2 (P = 0.000, HR = 3.09), and
positive LVI were 3.3 times at higher risk were compared to
negative value (P = 0.000). Patients with ER/PR receptors
negative were more likely to suffer from recurrence than
the ones with positive receptors (P = 0.018, HR = 1.43). Pa-
tients with positive lymph node were 2.7 times more than
the negative value (P = 0.000) and node ratio > 0.25 were
3 times more than nr≤ 0.25 in danger of recurrence (P =
0.000, HR = 3.30). DFS graphs of independent prognostic
factors that affected the disease free survival time of the pa-
tients with recurrence are represented in Figure 1.
In this study, variables effective on early recurrence
(less than one year after treatment) and late recurrence (af-
ter 5 years later treatment) were studied. 62 (21.60%) and 69
(24.04%) of patients experienced early and late recurrence.
8 variable evaluated with tumor size stratified in multivari-
ate cox regression analysis. The significant prognostic fac-
tor was hormone receptor (ER/PR) negative versus positive
(Haze .Ratio = 3.54, P = 0.003) and then lymph vascular in-
vasion (Haze .Ratio = 2.65, P = 0.038) (Table 5).
We also studied factors effective in late recurrence (af-
ter 5 years) and compared them to those of patients with
recurrence earlier than 5 years. We found that the most
effective factors in late recurrence were stage of disease
(stage 2 to stage1, haze ratio = 2.10, P = 0.000 and stage 3 to
2, haze ratio = 8.01, P = 0.000), and lymph vascular invasion
(haze ratio = 4.92, P = 0.007) (Table 6).
The independent prognostic factors that affected
death of the patients after relapse are presented in Table 7.
Cox regression analysis showed that the factors affecting
the death in patients suffering from recurrence, 10 vari-
ables were studied where prognostic factors, such as grade
3 of the disease (P = 0.000, HR = 5.97), and recurrence
site and disease free survival. The hazard of death in the
patients with visceral recurrence (P = 0.001, HR = 8.04)
was more than loco regional and in the patients with bone
recurrence (P = 0.031, HR = 4.42) it was more than local
recurrence. Patients with DFS more than 5 years (P = 0.001,
HR = 0.076) were in the lowest risk as opposed to the ones
with DFS lower than 1 year. In Figure 2 represented disease
free survival time graph in bases of recurrence site. 56.86%
of the patients (178 individuals) survived and 43.13% (135
individuals) died at the end of the follow-up period.
5. Discussion
Breast cancer patients are at recurrence risk even years
after receiving treatment which is the highest during the 2
- 3 years after detection of the primary tumor (9). Distant
metastasis is the most prevalent form of recurrence and
the main cause of death in breast cancer patients. Prog-
nostic factors, estimated to cause recurrence and distant
metastasis following the treatment in stages 1, 2, and 3
of breast cancer, include pathologic of breast cancer, tu-
mor grade, tumor size, involvement of lymph node, and
hormone receptors’ status of ER, PR, and HER2 (13, 14).
In a study conducted on recurrence factors, involvement
of lymph nodes, tumor grade, tumor size, and age were
strong predictors of recurrence, and estrogen receptors
had a medium effect (15).
Our study, a retrospective study, analyzed 313 breast
cancer patients from 1604 women suffering from breast
cancer in Iran.In our initial investigation of effective fac-
tors in recurrence, similar to previous studies, the most ef-
fective factors in breast cancer recurrence were lower ages,
involvement of axillary lymph node, negative estrogen re-
ceptor, higher grades of tumor, higher stages of disease,
and lymph vascular invasion.
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Table 1. Characteristics of Patients with Recurrence
Variables of Recurrence Cases
Age Freq Percent
≤ 40 year 103 32.91
> 40 year 206 65.81
Unknown 4 1.28
Total 313 100.00
Stage
1 18 5.75
2 99 31.63
3 119 38.02
Unknown 77 24.60
Total 313 100.00
Lvi
Negative 82 26.20
Positive 122 38.98
Unknown 109 34.82
Total 313 100.00
ERandPR - a 93 29.71
ER/PR + 145 46.33
Unknown 75 23.96
Total 313 100.00
Tumor size
≤ 2 cm 46 14.70
2 - 5 cm 108 34.50
> 5 cm 83 26.52
Unknown 76 24.28
Total 313 100.00
Nodal ratio
≤ 0.25 103 32.91
> 0.25 130 41.53
Unknown 80 25.56
Total 313 100.00
Her2 receptorb
Negative 150 47.92
Positive 72 23.00
Unknown 91 29.07
Total 313 100.00
Lymph node
Negative 66 21.09
Positive 247 78.91
Unknown 0
Total 313 100.00
aEstrogen and progesterone receptor.
bhuman epidermal growth factor receptor2.4 Iran J Cancer Prev. In Press(In Press):e5747.
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Table 2. Recurrence Site
Case (%) Without Other Site With Other Site
Bone 86 (27.4%) 58 28
Lung and pleura 50 (15.97%) 38 12
Liver 36 (11.50%) 28 8
Brain 36 (11.50%) 27 9
Spleen 1 (0.3%) 1 0
Ovary 1 (0.3%) 1 0
Total of distant recurrence 210 (67.09%)
Local recurrence(soft tissue or chest wall) 67 (21.40%) 60 7
Regional lymph node 9 (2.87%) 8 1
Total loco regional recurrence 76 (24.28%)
Unknown 27 (8.62%)
Total recurrence 313 (100%)
Table 3. Life Table for DFSa
DFS Interval Total Recurrence Lost Survival Confidence Interval
< 1 year 1604 65 269 0.9558 (95%) 0.9439 - 0.9651
1 – 5 year 1270 156 674 0.7960 (80%) 0.7702 - 0.8192
> 5 year 440 69 371 0.5802 (58%) 0.5316 - 0.6255
a Disease Free Survival.
Table 4. Univariate and Multivariate Cox Regression Analysis of Prognostic Factor Related to Recurrence
Variable Univariate Model Multivariat Model
-t Hazard Ratio P > Z CI Hazard Ratio P > Z CI
Age
≤ 40 years 1 1
> 40 years 0.8247517 0.509 0.4654633-1.461373 0.935226 0.000 0.0348639 - 0.2508747
Stage
1 1 1
2 1.93933 0.044 1.016936-3.698366 1.878633 0.199 0.717592 - 4.918202
3 5.002811 0.000 2.639037-9.483808 3.155098 0.054 0.9785072 - 10.17329
Grade
1 1 1
2 1.395404 0.271 0.7714729-2.523943 0.8933336 0.792 0.3859236 - 2.067883
3 3.093782 0.000 1.712921-5.587816 1.465748 0.388 0.6152919 - 3.491703
Lvia
Negative 1 1
Positive 3.321855 0.000 2.422798-4.554536 1.964151 0.029 1.047363 - 2.414612
Nodal ratio
≤ 0.25 1 1
> 0.25 3.302592 0.000 2.456099-4.440828 1.246362 0.446 0.7074119 - 2.195917
Her2
Negative 1 1
Positive 1.133748 0.457 0.8143957-1.57833 0.7898445 0.295 0.5076873 - 1.228816
Lymph node
Negative 1 1
Positive 2.792676 0.000 2.017784-3.865149 1.161708 0.635 0.6250764 - 2.159039
ER/PR positive 1 1
ER and PR negative 1.4388 0.018 1.064871-1.944034 1.502363 0.057 0.9882056 - 2.284032
a lymph vascular invasion.
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Table 5. Multivariate Cox Regression Analysis of Patients with Early Recurrence (< 1 year)
_t Haz.ratio Std.Err. z P > z [95% conf.Interval]
Age < 40 years 1
Age > 40 year 0.6183031 0.2645267 -1.12 0.261 0.2673219 - 1.430106
Stage 1
2 0.4089083 0.5078259 -0.72 0.471 0.35852 - 4.663788
3 1.749409 2.481231 0.39 0.693 0.1085453 - 28.19493
Grad 1
2 1.26732 1.345275 0.22 0.823 0.1582434 - 10.14955
3 1.330639 1.411012 0.27 0.788 0.1665114 - 10.6335
LVI - 1
LVI + 2.651709 1.246138 2.08 0.038 1.055636 - 6.660969
Receptor
ER and PR + 1
ER/PR - 3.547485 1.51482 2.97 0.003 1.536197 - 8.19208
Her2 - 1
Her2 + 0.8379649 0.3816025 -0.39 0.698 0.3432381 - 2.045767
Lymph - 1
Lymph+ 0.6939046 0.6114455 -0.41 0.678 0.1233813 - 3.902564
Table 6. Multivariate Cox Regression Analysis of Patients with Late Recurrence (After 5 Years)
t Haz.Ratio Std.Err. Z P > Z [95% conf. Interval]
Age < 40 1
Age > 40 0.4847364 0.263480 -1.33 0.183 0.1670446 - 1.406627
Stage
2 2.10e+10 1.89e+10 26.33 0.000 3.58e+09 - 1.23e+11
3 8.01e+10
Grade
1 1
2 0.8064342 0.914841 -1.19 0.850 0.0872856 - 7.450669
3 0.4746659 0.582240 -0.61 0.544 0.0428822 - 5.254103
Lvi- 1
Lvi+ 4.921768 2.90038 2.70 0007 1.550641 - 15.6218
ER/PR+ 1
ERandPR- 0.539461 0.314967 -1.06 0.290 0.1717837 - 1.694098
HER2- 1
HER2+ 0.7312887 0.438836 -0.52 0.602 0.2255769 - 2.370736
Lymph- 1
Lymph+ 0.4278776 0.304574 -1.19 0.233 0.1060257 - 1.726744
6 Iran J Cancer Prev. In Press(In Press):e5747.
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Figure 1. Disease Free Survival Graphs in Patients with Breast Cancer Recurrence (Variables Were Significantly Influencing on DFS in Univariate Analysis)
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P = 0.000; Receptor 0 = estrogen/progesterone receptor negative; Receptor 1= estrogen andprogesterone receptorpositive; Lvi 0 = lymphovascular invasion negative; Lvi 1 =
lymphovascular invasion positive.
Figure 2. Disease Free Survival Graph in Bases of Recurrent Site
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Log rank test, P = 0.000.
Akbari et al. in a study on 258 breast cancer patients,
concluded that the recurrence risk factors are negative es-
trogen receptor, and lymph vascular invasion, but other
demographic, pathologic and biologic factors (e.g. proges-
terone, HER2 and P53) were not significantly effective (16).
In recent decades, due to the increase in survival in
breast cancer patients as a result of advancements in di-
agnosis and treatment methods, studies have moved to-
wards investigation of effective factors in early and late re-
currence. In a study by Erick Sta et al. which focused on
factors effective in less than 2-year recurrence, the major
factors effective in early recurrence were tumor stage, and
size and lymph node status. This study showed that her2
receptor overexpression was not the only determining fac-
tor, but triple negative breast cancer patients were likely to
experience early metastasis (9).
Although several studies in Iran have investigated ef-
fective factors in recurrence and metastasis (17-19), studies
conducted on effective factors in early and late recurrence
are scarce. In this study, we examined effective factors in re-
currence (as mentioned earlier), and effective prognostic
factors in too early recurrence (less than 1 year) and longer
than 5-year recurrence.
Tumor size and the number of involved lymph nodes
which shows the expansion of the tumor, were pro-
nounced the most effective prognostic factors in breast
cancer recurrence (20). However, too early recurrence of
tumor as a result of the treatment is considered a factor be-
yond the recurrence risk factors. Previous studies showed
that nodal stage in early recurrence was earlier than 5 years
(21). And the most effective factor in late recurrence after 5
years was advanced stage of primary tumor (22).
The most important factors in early recurrence, in a
study conducted to examine the effective factors in recur-
rence earlier than 5 years and later than 5 years on posi-
tive receptor patients, were higher nodal stage, higher his-
tologic grade, and age < 35 years, which had insignificant
Iran J Cancer Prev. In Press(In Press):e5747. 7
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Table 7. Multivariate Cox Regression Analysis of Prognostic Factors Related to Death
in Breast Cancer Patients
Variable Haz .ratio P > Z 95% conf. Interval
Age
≤ 40 1
> 40 0.1669144 0.042 0.0296742 - 0.9388759
Stage
1 1
2 4.799454 0.404 0.1205164 - 191.1338
3 0.7144707 0.870 0.0125541 - 40.6615
Grade
1 1
2 4.50e+08
3 5.97e+08 0.000 2.52e+08 - 1.42e+09
Lvi
Negative 1
Positive 0.4762029 0.158 0.1699365 - 1.334435
ER/PR + 1
ERandPR - 1.587114 0.334 0.6222278 - 4.048245
Her2 receptor
Negative 1
Positive 1.413258 0.417 0.6133221 - 3.256525
Lymph node
Negative 1
Positive 3.436266 0.069 0.9077252 - 13.00826
DFS
≤ 1year 1
2 - 5 year 0.2367647 0.043 0.0587704 - 0.9538395
≥ 5year 0.0766429 0.001 0.0157753 - 0.3723626
Site of recurrence
Locoregional 1
Visceral 8.040411 0.001 2.289926 - 28.23158
Bon 4.424882 0.031 1.14936 - 17.0352
effects on late recurrence. The effective factor in decreas-
ing late recurrence in these patients was endocrine ther-
apy (23). Moreover, another study in this area concluded
that lymph node status and tumor size were predictive fac-
tors of late recurrence and death in patients with positive
receptor after menopause (24).
Multivariate analysis showed that the most effective
factors in early recurrence among our patients were estro-
gen and progesterone receptor status, and the most effec-
tive factor in late recurrence in these patients was stage
of disease. Lymph vascular invasion was the common ef-
fective factor in both groups. In this study, exploring dif-
ferences between effective factors in early and late recur-
rence showed that the most effective factors in too early
recurrence were the tumor biologic factors (estrogen and
progesterone receptor negative), but we did not observe
receptor effects in late recurrence. The reason is that the
biggest effect of estrogen and progesterone receptor sta-
tus in increasing recurrence risk is in the first 3 years after
the treatment and goes after that (25). We also found that
the most effective factor in late recurrence after 5 years was
stage of disease which is in line with the findings of some
other studies (26).
Many studies on hormone receptors have shown that
negative estrogen and progesterone receptors increase re-
sponse to weakly treatment, among breast cancer patients
(27, 28).
Although breast cancer survival has increased together
with recent advances in early diagnosis techniques and ad-
juvant treatments, metastatic patients have varied survival
time, because the difference in survival time, determining
the prognostic factors for these patients is important.
Bone metastasis is the most common type of distant re-
currence in breast cancer patients (29). Our study supports
these findings. In the present study, 67.09% (210 patients)
were involved with distant organ metastasis and 24.28 %(
76 patients) involved with loco regional recurrence. The
most common type of distant metastasis is seen the bone
metastasis (40.95% of total distant metastasis).
Patients with bone metastasis generally have longer
survival time as compared with the patients with other or-
gan distant metastasis (30). Several studies showed that
the patients with longer interval of recurrence develop-
ment had longer survival (31). Factors affecting the prog-
nosis in the people with recurrence are shorter DFS, recur-
rence site, the extent of involvement (single or multiple),
hormone receptors status, and level of response to treat-
ment (26).
A recent consensus paper reported that multiple fac-
tors including HER2 status, site/extent of recurrence or
metastasis, DFS, and adjuvant treatments are effective in
patients’ prognosis (32, 33).
In search of factors affecting death in patients with
recurrence, this study found that factors such as higher
grades of tumors, recurrence site, and DFS played a sig-
nificant role. Patients with loco regional recurrence had
a mean DFS of 4.3 years (CI = 3.27 - 5.40) and those with
visceral recurrence had a mean DFS of 3.3 (CI = 2.7 - 4.02),
which in turn causes better prognosis in patients with
longer DFS (with loco regional recurrence). Risk of death
in visceral recurrence was more than loco regional recur-
rence and in patients with bone recurrence, it was more
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than loco regional recurrence but less than other distant
metastasis or visceral metastasis.
Patients with tumor grade 3 had a higher risk of death
than those with grade 1. In terms of DFS, patients with DFS
> 5 years had the best prognosis and lower death risk com-
pared to patients with DFS < 1.
A drawback of this study was that we did not investi-
gate adjuvant therapy in recurrence risk which should be
considered to avoid bias in future studies, it. Future re-
search can be conducted to study more patients with re-
currence as well as treatment types. According to the find-
ings of this study, a better understanding of invasive tu-
mor features in breast cancer patients together with the
risk factors in individual patients can lead to individual
treatments not general guidelines. Because each patient
has a unique set of demographic, clinic-pathologic and bi-
ologic factors which create a whole different context for re-
currence.
5.1. Conclusion
This study was aimed to find risk factors of early and
late recurrence in breast cancer patients; so that it can de-
tect subcategories of patients with recurrence risk to bet-
ter choose the treatments and provide better follow up
and care to minimize the risk of recurrence and increase
survival. Also, to avoid unnecessary treatments, tests and
imaging in follow up in the case of lower risk patients with
the purpose of minimizing expenses and physical side ef-
fect.
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